Biofrontera (BFRI) Revenue & Revenue Breakdown
Biofrontera Revenue Highlights
Latest Revenue (Y)
$34.01M
Latest Revenue (Q)
$7.83M
Main Segment (Y)
Government and Payor Rebates
Biofrontera Revenue by Period
Biofrontera Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $34.01M | 18.59% |
| 2022-12-31 | $28.67M | 18.98% |
| 2021-12-31 | $24.10M | 27.86% |
| 2020-12-31 | $18.85M | -28.01% |
| 2019-12-31 | $26.18M | - |
Biofrontera generated $34.01M in revenue during NA 2023, up 18.59% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Biofrontera Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $7.83M | -0.89% |
| 2024-03-31 | $7.90M | -25.43% |
| 2023-12-31 | $10.60M | 19.34% |
| 2023-09-30 | $8.88M | 51.83% |
| 2023-06-30 | $5.85M | -33.04% |
| 2023-03-31 | $8.73M | -13.91% |
| 2022-12-31 | $10.14M | 134.71% |
| 2022-09-30 | $4.32M | -3.03% |
| 2022-06-30 | $4.46M | -54.29% |
| 2022-03-31 | $9.75M | 6.36% |
| 2021-12-31 | $9.17M | 111.54% |
| 2021-09-30 | $4.33M | -25.98% |
| 2021-06-30 | $5.86M | 23.42% |
| 2021-03-31 | $4.74M | -44.66% |
| 2020-12-31 | $8.57M | 163.59% |
| 2020-09-30 | $3.25M | 35.39% |
| 2020-06-30 | $2.40M | -48.04% |
| 2020-03-31 | $4.62M | - |
Biofrontera generated $7.83M in revenue during Q2 2024, up -0.89% compared to the previous quarter, and up 89.67% compared to the same period a year ago.
Biofrontera Revenue Breakdown
Biofrontera Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Prompt Pay Discounts | $6.00K | $67.00K | $7.00K |
| Government and Payor Rebates | $310.00K | $264.00K | $157.00K |
| Co-pay Assistance Program | $165.00K | $675.00K | - |
| Returns | $52.00K | $53.00K | $180.00K |
| CoPay Assistance Program | - | - | $374.00K |
Biofrontera's latest annual revenue breakdown by segment (product or service), as of Dec 23: Government and Payor Rebates (58.16%), Co-pay Assistance Program (30.96%), Returns (9.76%), and Prompt Pay Discounts (1.13%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Prompt Pay Discounts | $6.00K | - | $6.00K | - | $2.00K | $39.00K | $3.00K | $3.00K | $17.00K | $2.00K | $5.00K |
| Returns | $52.00K | - | $52.00K | $51.00K | $49.00K | - | - | - | $5.00K | $38.00K | $142.00K |
| Government and Payor Rebates | $82.00K | $79.00K | $231.00K | $20.00K | $39.00K | $95.00K | $34.00K | $63.00K | $52.00K | $44.00K | - |
| Co-pay Assistance Program | - | - | $145.00K | $71.00K | $71.00K | $266.00K | $100.00K | - | - | - | - |
| CoPay Assistance Program | - | - | - | - | - | - | - | $150.00K | $150.00K | $111.00K | - |
| Co Pay Assistance Program | - | - | - | - | - | - | - | - | - | - | $263.00K |
| Government And Payor Rebates | - | - | - | - | - | - | - | - | - | - | $113.00K |
Biofrontera's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Government and Payor Rebates (58.57%), Returns (37.14%), and Prompt Pay Discounts (4.29%).
Biofrontera Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTPI | Petros Pharmaceuticals | $5.82B | $1.39M |
| PROC | Procaps Group | $409.92M | $118.41M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| ACOR | Acorda Therapeutics | $102.42M | $20.29M |
| CPIX | Cumberland Pharmaceuticals | $39.55M | $9.85M |
| BFRI | Biofrontera | $34.01M | $7.83M |
| AGRX | Agile Therapeutics | $19.59M | $5.58M |
| GHSI | Guardion Health Sciences | $12.25M | $36.35K |
| JUPW | Safety Shot | $6.20M | $910.01K |
| EVOK | Evoke Pharma | $5.18M | $1.74M |
| AKAN | Akanda | $2.16M | $762.61K |
| SXTC | China SXT Pharmaceuticals | $1.97M | $939.58K |
| LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |
| SHPH | Shuttle Pharmaceuticals | - | - |
| IXHL | Incannex Healthcare | - | - |
| HUGE | FSD Pharma | - | - |
| PRFX | PainReform | - | - |
| RGC | Regencell Bioscience | - | - |
BFRI Revenue FAQ
What is Biofrontera’s yearly revenue?
Biofrontera's yearly revenue for 2023 was $34M, representing an increase of 18.59% compared to 2022. The company's yearly revenue for 2022 was $28.67M, representing an increase of 18.98% compared to 2021. BFRI's yearly revenue for 2021 was $24.1M, representing an increase of 27.86% compared to 2020.
What is Biofrontera’s quarterly revenue?
Biofrontera's quarterly revenue for Q2 2024 was $7.83M, a -0.89% decrease from the previous quarter (Q1 2024), and a 33.91% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $7.9M, a -25.43% decrease from the previous quarter (Q4 2023), and a -9.53% decrease year-over-year (Q1 2023). BFRI's quarterly revenue for Q4 2023 was $10.6M, a 19.34% increase from the previous quarter (Q3 2023), and a 4.46% increase year-over-year (Q4 2022).
What is Biofrontera’s revenue growth rate?
Biofrontera's revenue growth rate for the last 3 years (2021-2023) was 41.10%, and for the last 5 years (2019-2023) was 29.88%.
What are Biofrontera’s revenue streams?
Biofrontera's revenue streams in c 23 are Prompt Pay Discounts, Government and Payor Rebates, Co-pay Assistance Program, and Returns. Prompt Pay Discounts generated $6K in revenue, accounting 1.13% of the company's total revenue, down -91.04% year-over-year. Government and Payor Rebates generated $310K in revenue, accounting 58.16% of the company's total revenue, up 17.42% year-over-year. Co-pay Assistance Program generated $165K in revenue, accounting 30.96% of the company's total revenue, down -75.56% year-over-year. Returns generated $52K in revenue, accounting 9.76% of the company's total revenue, down -1.89% year-over-year.
What is Biofrontera’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Biofrontera was Government and Payor Rebates. This segment made a revenue of $310K, representing 58.16% of the company's total revenue.